Nutriband Inc (NTRB)

$4.87

-0.06

(-1.32%)▲

Market is closed - opens 7 PM, 23 May 2024

Insights on Nutriband Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 427.84K → 524.61K (in $), with an average increase of 9.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -829.17K → -1.88M (in $), with an average decrease of 39.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 6.7%

Performance

  • $4.48
    $5.15
    $4.87
    downward going graph

    8.01%

    Downside

    Day's Volatility :13.01%

    Upside

    5.44%

    downward going graph
  • $1.53
    $6.00
    $4.87
    downward going graph

    68.58%

    Downside

    52 Weeks Volatility :74.5%

    Upside

    18.83%

    downward going graph

Returns

PeriodNutriband IncIndex (Russel 2000)
3 Months
98.19%
0.0%
6 Months
93.57%
0.0%
1 Year
51.85%
0.0%
3 Years
-13.94%
-20.1%

Highlights

Market Capitalization
53.2M
Book Value
$0.73
Earnings Per Share (EPS)
-0.69
Wall Street Target Price
18.0
Profit Margin
-263.05%
Operating Margin TTM
-249.01%
Return On Assets TTM
-35.88%
Return On Equity TTM
-73.08%
Revenue TTM
2.1M
Revenue Per Share TTM
0.26
Quarterly Revenue Growth YOY
-0.6%
Gross Profit TTM
750.4K
EBITDA
-4.6M
Diluted Eps TTM
-0.69
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Nutriband Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 269.61%

Current $4.87
Target $18.00

Company Financials

FY19Y/Y Change
Revenue
245.3K
-
Net Income
-3.3M
↑ 24.67%
Net Profit Margin
-1.4K%
-
FY20Y/Y Change
Revenue
370.6K
↑ 51.11%
Net Income
-2.8M
↓ 16.1%
Net Profit Margin
-754.1%
↑ 604.01%
FY21Y/Y Change
Revenue
943.7K
↑ 154.61%
Net Income
-3.2M
↑ 14.97%
Net Profit Margin
-340.52%
↑ 413.58%
FY22Y/Y Change
Revenue
1.4M
↑ 50.7%
Net Income
-8.4M
↑ 162.09%
Net Profit Margin
-592.23%
↓ 251.71%
FY23Y/Y Change
Revenue
2.1M
↑ 46.23%
Net Income
-4.8M
↓ 42.88%
Net Profit Margin
-231.33%
↑ 360.9%
FY24Y/Y Change
Revenue
2.1M
↑ 0.27%
Net Income
-5.5M
↑ 14.02%
Net Profit Margin
-263.04%
↓ 31.71%
Q1 FY23Q/Q Change
Revenue
527.5K
↓ 14.64%
Net Income
-1.7M
↑ 54.41%
Net Profit Margin
-315.96%
↓ 141.29%
Q2 FY23Q/Q Change
Revenue
476.9K
↓ 9.59%
Net Income
-1.0M
↓ 39.06%
Net Profit Margin
-212.98%
↑ 102.98%
Q3 FY23Q/Q Change
Revenue
655.9K
↑ 37.53%
Net Income
-829.2K
↓ 18.37%
Net Profit Margin
-126.41%
↑ 86.57%
Q4 FY23Q/Q Change
Revenue
427.8K
↓ 34.77%
Net Income
-1.8M
↑ 112.25%
Net Profit Margin
-411.36%
↓ 284.95%
Q1 FY24Q/Q Change
Revenue
524.6K
↑ 22.62%
Net Income
-1.9M
↑ 6.88%
Net Profit Margin
-358.54%
↑ 52.82%
Q2 FY24Q/Q Change
Revenue
524.6K
↑ 0.0%
Net Income
-1.9M
↑ 0.0%
Net Profit Margin
-358.54%
↑ 0.0%
FY19Y/Y Change
Total Assets
2.8M
↑ 1602.63%
Total Liabilities
403.0K
↑ 828.78%
FY20Y/Y Change
Total Assets
2.2M
↓ 21.72%
Total Liabilities
2.0M
↑ 401.81%
FY21Y/Y Change
Total Assets
9.9M
↑ 351.71%
Total Liabilities
2.8M
↑ 39.22%
FY22Y/Y Change
Total Assets
12.7M
↑ 28.33%
Total Liabilities
880.4K
↓ 68.73%
FY23Y/Y Change
Total Assets
9.5M
↓ 25.77%
Total Liabilities
883.4K
↑ 0.34%
FY24Y/Y Change
Total Assets
7.5M
↓ 20.51%
Total Liabilities
1.1M
↑ 22.13%
Q1 FY23Q/Q Change
Total Assets
9.5M
↓ 11.37%
Total Liabilities
883.4K
↓ 5.79%
Q2 FY23Q/Q Change
Total Assets
8.7M
↓ 8.26%
Total Liabilities
955.8K
↑ 8.2%
Q3 FY23Q/Q Change
Total Assets
9.9M
↑ 13.8%
Total Liabilities
3.0M
↑ 211.97%
Q4 FY23Q/Q Change
Total Assets
8.5M
↓ 13.67%
Total Liabilities
2.8M
↓ 5.71%
Q1 FY24Q/Q Change
Total Assets
7.5M
↓ 11.8%
Total Liabilities
1.1M
↓ 61.63%
Q2 FY24Q/Q Change
Total Assets
7.5M
↑ 0.0%
Total Liabilities
1.1M
↑ 0.0%
FY19Y/Y Change
Operating Cash Flow
-1.1M
↑ 1090.49%
Investing Cash Flow
-404.2K
↑ 0.0%
Financing Cash Flow
2.0M
↑ 2916.77%
FY20Y/Y Change
Operating Cash Flow
-894.5K
↓ 19.09%
Investing Cash Flow
67.0K
↓ 116.58%
Financing Cash Flow
430.3K
↓ 78.31%
FY21Y/Y Change
Operating Cash Flow
-297.1K
↓ 66.79%
Investing Cash Flow
67.0K
↑ 0.0%
Financing Cash Flow
371.9K
↓ 13.57%
FY22Y/Y Change
Operating Cash Flow
-2.8M
↑ 845.69%
Investing Cash Flow
-81.6K
↓ 221.79%
Financing Cash Flow
7.6M
↑ 1951.96%
FY23Y/Y Change
Operating Cash Flow
-3.0M
↑ 6.34%
Investing Cash Flow
-79.3K
↓ 2.81%
Financing Cash Flow
160.1K
↓ 97.9%
Q1 FY23Q/Q Change
Operating Cash Flow
-814.0K
↑ 56.41%
Investing Cash Flow
-10.0K
↑ 687.97%
Financing Cash Flow
-6.9K
↑ 4.98%

Technicals Summary

Sell

Neutral

Buy

Nutriband Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nutriband Inc
Nutriband Inc
39.41%
93.57%
51.85%
-13.94%
-13.94%
Moderna, Inc.
Moderna, Inc.
37.56%
83.82%
13.37%
-12.47%
553.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
10.42%
24.29%
32.26%
98.6%
210.52%
Novo Nordisk A/s
Novo Nordisk A/s
7.9%
30.89%
58.53%
230.87%
458.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.52%
25.13%
30.01%
109.26%
156.43%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nutriband Inc
Nutriband Inc
NA
NA
NA
0.0
-0.73
-0.36
NA
0.73
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.46
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.16
29.16
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.83
45.83
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.9
28.9
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nutriband Inc
Nutriband Inc
Buy
$53.2M
-13.94%
NA
-263.05%
Moderna, Inc.
Moderna, Inc.
Buy
$54.0B
553.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.8B
210.52%
29.16
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$592.1B
458.51%
45.83
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.1B
156.43%
28.9
39.46%

Institutional Holdings

  • Vanguard Group Inc

    0.79%

  • Geode Capital Management, LLC

    0.53%

  • State Street Corporation

    0.16%

  • AlphaQ Advisors LLC

    0.11%

  • Atria Wealth Solutions, Inc.

    0.10%

  • Advisor Group Holdings, Inc.

    0.07%

Company Information

nutriband inc. is a health and pharmaceutical company based in, oviedo, florida. nutriband's primary focus is on transdermal and topical technologies for product development.

Organization
Nutriband Inc
Employees
0
CEO
Mr. Serguei Melnik
Industry
Health Technology

Discover More

FAQs